Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis

Obesity Reviews

Volumn 17, Issue 10, 2016, Pages 1001-1011

  Zomer, E ^a,b   Gurusamy, K ^b   Leach, R ^a   Trimmer, C ^a   Lobstein, T ^a   Morris, S ^b   James, W P T ^a,c   Finer, N ^a,b  

^a WORLD OBESITY FEDERATION   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Cardiovascular disease; cardiovascular risk factors; obesity; weight loss

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; GLUCOSE BLOOD LEVEL; HUMAN; META ANALYSIS; OBESITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

EID: 84986628195     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12433     Document Type: Review

References (36)

1. The Health and Social Care Information Centre. Statistics on Obesity, Physical Activity and Diet: England, 2015. Health and Social Care Information Centre: England, 2015.
2. Foresight. Tackling Obesities: Future Choices – Project Report. Foresight: United Kingdom, 2007.
3. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009; 53: 1925–1932.
4. Bray GA. Risks of obesity. Endocrinol Metab Clin North Am 2003; 32: 787–804.
5. Krauss RM, Winston M, Fletcher BJ, Grundy SM. Obesity: impact on cardiovascular disease. AHA Con Proc 1998; 98: 1472–1476.
6. Runge CF. Economic consequences of the obese. Diabetes 2007; 56: 2668–2672.
7. McKinsey Global Institute. Overcoming Obesity: An Initial Economic Analysis. McKinsey and Company: United Kingdom, 2014.
8. Wing RR, Lang W, Wadden TA et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011; 34: 1481–1486.
9. Scottish Intercollegiate Guidelines Network. SIGN Guideline 115. Management of Obesity. A National Clinical Guideline. SIGN: Scotland, 2010.
10. Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 1997; 21/1: S5–S9.
11. Van Gaal LF, Mertens IL, Ballaux D. What is the relationship between risk factor reduction and degree of weight loss? Eur Heart J Suppl 2005; 7/L: L21–L26.
12. Dombrowski SU, Avenell A, Sniehotta FF. Behavioural interventions for obese adults with additional risk factors for morbidity: systematic review of effects of behaviour, weight and disease risk factors. Obes Facts 2010; 3: 377–396.
13. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.
14. Capewell S, Ford ES, Croft JB, Critchley JA, Greenlund KJ, Labarthe DR. Cardiovascular risk factor trends and potential for reducing coronary heart disease mortality in the United States of America. Bull World Health Organ 2010; 88: 120–130.
15. Charakida M, Khan T, Johnson W et al. Lifelong patterns of BMI and cardiovascular phenotype in individuals aged 60-64 years in the 1946 British birth cohort study: an epidemiological model. Lancet Diabetes Endocrinol 2014; 2: 648–654.
16. Belalcazar LM, Ballantyne CM, Lang W et al. Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the Look AHEAD study. Arterioscler Throm Vasc Biol 2011; 31: 1689–1695.
17. Vartiainen E, Laatikainen T, Peltonen M et al. Thirty-five-year trends in cardiovascular risk factors in Finland. Int J Epidemiol 2010; 39: 504–518.
18. Ornish D, Scherwitz LW, Billings JH et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA 1998; 280: 2001–2007 Erratum in: JAMA 1999; 281: 1380.
19. Hjermann I, Velve Byre K, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet 1981; 2: 1303–1310.
20. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. NEJM 2002; 346: 393–403.
21. Li G, Zhang P, Wang J et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008; 371: 1783–1789.
22. Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. Diabetes Care 1997; 20: 537–544.
23. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. NEJM 2001; 344: 1343–1350.
24. Wenger NK. Prevention of cardiovascular disease: highlights for the clinician of the 2013 American College of Cardiology/American Heart Association guidelines. Clin Cardiol 2014; 37: 239–251.
25. National Collaborating Centre for Primary Care and the Centre for Public Health Excellence at NICE. Obesity: Guidance on the Prevention, Identification, Assessment and Management of Overweight and Obesity in Adults and Children. National Institute for Health and Care Excellence clinical guideline 43. NICE: United Kingdom, 2006.
26. National Institutes of Health in cooperation with the National Heart, Lung, and Blood Institute and North American Association for the Study of Obesity. The Practical Guide: Identification, Evaluation and Treatment of Overweight and Obesity in Adults. National Heart, Lung, and Blood Institute's (NHLBI) Obesity Education Initiative: USA, 2000.
27. Blackburn G. Effect of degree of weight loss on health benefits. Obes Res 1995; 3/2: 211 s–216 s.
28. Ross R, Dagnone D, Jones PJH et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men: a randomised, controlled trial. Ann Intern Med 2000; 133: 92–103.
29. Li Z, Maglione M, Tu W, Mojica W, Arterburn D et al. Meta –analysis: pharmacological treatment of obesity. Ann Intern Med 2005; 142: 532–546.
30. Thomas D, Elliot EJ, Naughton GA. Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006; 3.
31. Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, Kalhan S. Effects of moderate weight loss and Orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 2004; 27: 33–40.
32. Jacob S, Rabbia M, Meier MK, Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab 2009; 11: 361–71.
33. Caterson ID, Finer N, Coutinho W et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab 2012; 14: 523–530.
34. Affuso O, Kaiser KA, Carson TL et al. Association of run-in periods with weight loss in obesity randomized controlled trials. Obes Rev 2014; 15: 68–73.
35. Juni P, Holenstein F, Sterne J, Bartlett C, Egger M. Direction and impact of language bias in meta-analyses of controlled trials: empirical study. Int J Epidemiol 2002; 31: 115–123.
36. Magkos F, Fraterrigo G, Yoshino J et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591–601.